Nothing Special   »   [go: up one dir, main page]

WO2008073923A3 - Mirna regulated genes and pathways as targets for therapeutic intervention - Google Patents

Mirna regulated genes and pathways as targets for therapeutic intervention Download PDF

Info

Publication number
WO2008073923A3
WO2008073923A3 PCT/US2007/087038 US2007087038W WO2008073923A3 WO 2008073923 A3 WO2008073923 A3 WO 2008073923A3 US 2007087038 W US2007087038 W US 2007087038W WO 2008073923 A3 WO2008073923 A3 WO 2008073923A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathways
targets
therapeutic intervention
regulated genes
mirna regulated
Prior art date
Application number
PCT/US2007/087038
Other languages
French (fr)
Other versions
WO2008073923A2 (en
Inventor
Mike Byrom
Charles D Johnson
David Brown
Andreas G Bader
Original Assignee
Asuragen Inc
Mike Byrom
Charles D Johnson
David Brown
Andreas G Bader
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asuragen Inc, Mike Byrom, Charles D Johnson, David Brown, Andreas G Bader filed Critical Asuragen Inc
Priority to AU2007333110A priority Critical patent/AU2007333110A1/en
Priority to CA002671302A priority patent/CA2671302A1/en
Priority to EP07871694A priority patent/EP2102341A2/en
Priority to CA002671270A priority patent/CA2671270A1/en
Priority to US11/967,663 priority patent/US20090175827A1/en
Priority to AU2007342068A priority patent/AU2007342068A1/en
Priority to PCT/US2007/089206 priority patent/WO2008085797A2/en
Priority to EP07871756A priority patent/EP2102342A2/en
Publication of WO2008073923A2 publication Critical patent/WO2008073923A2/en
Publication of WO2008073923A3 publication Critical patent/WO2008073923A3/en
Priority to IL199161A priority patent/IL199161A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-16, using miR-16 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.
PCT/US2007/087038 2006-12-08 2007-12-10 Mirna regulated genes and pathways as targets for therapeutic intervention WO2008073923A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2007333110A AU2007333110A1 (en) 2006-12-08 2007-12-10 miRNA regulated genes and pathways as targets for therapeutic intervention
CA002671302A CA2671302A1 (en) 2006-12-08 2007-12-10 Mirna regulated genes and pathways as targets for therapeutic intervention
EP07871694A EP2102341A2 (en) 2006-12-08 2007-12-10 Mirna regulated genes and pathways as targets for therapeutic intervention
CA002671270A CA2671270A1 (en) 2006-12-29 2007-12-31 Mir-16 regulated genes and pathways as targets for therapeutic intervention
US11/967,663 US20090175827A1 (en) 2006-12-29 2007-12-31 miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
AU2007342068A AU2007342068A1 (en) 2006-12-08 2007-12-31 miR-16 regulated genes and pathways as targets for therapeutic intervention
PCT/US2007/089206 WO2008085797A2 (en) 2006-12-08 2007-12-31 miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
EP07871756A EP2102342A2 (en) 2006-12-08 2007-12-31 miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
IL199161A IL199161A0 (en) 2006-12-08 2009-06-04 mIR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86929506P 2006-12-08 2006-12-08
US60/869,295 2006-12-08
US88275806P 2006-12-29 2006-12-29
US60/882,758 2006-12-29

Publications (2)

Publication Number Publication Date
WO2008073923A2 WO2008073923A2 (en) 2008-06-19
WO2008073923A3 true WO2008073923A3 (en) 2008-12-11

Family

ID=39512449

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/087038 WO2008073923A2 (en) 2006-12-08 2007-12-10 Mirna regulated genes and pathways as targets for therapeutic intervention
PCT/US2007/089206 WO2008085797A2 (en) 2006-12-08 2007-12-31 miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2007/089206 WO2008085797A2 (en) 2006-12-08 2007-12-31 miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION

Country Status (5)

Country Link
EP (2) EP2102341A2 (en)
AU (2) AU2007333110A1 (en)
CA (1) CA2671302A1 (en)
IL (1) IL199161A0 (en)
WO (2) WO2008073923A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039256A2 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
US8513209B2 (en) 2007-11-09 2013-08-20 The Board Of Regents, The University Of Texas System Micro-RNAS of the MIR-15 family modulate cardiomyocyte survival and cardiac repair
WO2009075799A2 (en) 2007-12-05 2009-06-18 The Wistar Institute Of Anatomy And Biology Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
JP2010094122A (en) 2008-06-12 2010-04-30 Keio Gijuku Diagnosis-treatment option for head-and-neck tumor using micro-rna as biomarker
WO2010054233A1 (en) 2008-11-08 2010-05-14 The Wistar Institute Of Anatomy And Biology Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers
MX2012006560A (en) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration.
WO2013055911A1 (en) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Znf365/zfp365 biomarker predictive of anti-cancer response
SG10201600316SA (en) 2012-01-27 2016-02-26 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2017005773A1 (en) * 2015-07-07 2017-01-12 Universite de Bordeaux Use of catenin- beta 1-targeting micrornas for treating liver cancer
US11692226B2 (en) 2017-07-31 2023-07-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Genotyping of SNPs to stratify cancer risk
KR102200428B1 (en) * 2018-05-16 2021-01-08 주식회사 지놈앤컴퍼니 Pharmaceutical composition for preventing or treating cancer comprising lrit2 inhibitor as active ingredient
CN111972399B (en) * 2020-08-06 2021-11-30 温州医科大学 Preservation solution for maintaining activity of liver cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043387A2 (en) * 2002-11-13 2004-05-27 Thomas Jefferson University Compositions and methods for cancer diagnosis and therapy
WO2007033023A2 (en) * 2005-09-12 2007-03-22 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of bcl2-associated cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043387A2 (en) * 2002-11-13 2004-05-27 Thomas Jefferson University Compositions and methods for cancer diagnosis and therapy
WO2007033023A2 (en) * 2005-09-12 2007-03-22 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of bcl2-associated cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CALIN G A ET AL: "A MICRORNA SIGNATURE ASSOCIATED WITH PROGNOSIS AND PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 353, no. 17, 27 October 2005 (2005-10-27), pages 1793 - 1801, XP009058593, ISSN: 1533-4406 *
CALIN GEORGE ADRIAN ET AL: "Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance.", SEMINARS IN ONCOLOGY APR 2006, vol. 33, no. 2, April 2006 (2006-04-01), pages 167 - 173, XP008092955, ISSN: 0093-7754 *
CIMMINO AMELIA ET AL: "miR-15 and miR-16 induce apoptosis by targeting BCL2.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 27 SEP 2005, vol. 102, no. 39, 27 September 2005 (2005-09-27), pages 13944 - 13949, XP002484308, ISSN: 0027-8424 *
LINSLEY PETER S ET AL: "Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression.", MOLECULAR AND CELLULAR BIOLOGY MAR 2007, vol. 27, no. 6, March 2007 (2007-03-01), pages 2240 - 2252, XP002484310, ISSN: 0270-7306 *
MARTELLO GRAZIANO ET AL: "MicroRNA control of Nodal signalling.", NATURE 13 SEP 2007, vol. 449, no. 7159, 13 September 2007 (2007-09-13), pages 183 - 188, XP002484309, ISSN: 1476-4687 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs

Also Published As

Publication number Publication date
WO2008085797A8 (en) 2009-07-16
IL199161A0 (en) 2010-03-28
WO2008085797A3 (en) 2008-10-09
CA2671302A1 (en) 2008-06-19
AU2007342068A1 (en) 2008-07-17
WO2008073923A2 (en) 2008-06-19
AU2007333110A1 (en) 2008-06-19
EP2102341A2 (en) 2009-09-23
EP2102342A2 (en) 2009-09-23
WO2008085797A2 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
WO2009086156A3 (en) Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2008073920A3 (en) Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2009070805A3 (en) Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2008154333A3 (en) Mir-34 regulated genes and pathways as targets for therapeutic intervention
WO2008073919A3 (en) Mir-20 regulated genes and pathways as targets for therapeutic intervention
WO2008036741A3 (en) Mir-200 regulated genes and pathways as targets for therapeutic intervention
WO2008073923A3 (en) Mirna regulated genes and pathways as targets for therapeutic intervention
WO2009154835A3 (en) Compositions and methods related to mir-16 and therapy of prostate cancer
WO2008073921A3 (en) Mir-126 regulated genes and pathways as targets for therapeutic intervention
WO2008036776A3 (en) Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
WO2008073922A3 (en) Functions and targets of let-7 micro rnas
WO2009044899A1 (en) Nucleic acid capable of regulating the proliferation of cell
WO2009121152A8 (en) Gene signatures
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2011085066A3 (en) Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
WO2009134487A3 (en) Optimized methods for delivery of dsrna targeting the pcsk9 gene
WO2010065787A3 (en) Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
WO2009059318A3 (en) Genes and polymorphisms associated with amd
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2008082730A3 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2008036765A3 (en) Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2012058693A3 (en) Compositions and methods for inhibition of pcsk9 genes
WO2008141308A3 (en) Gene expression and pain

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780050607.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871694

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2671302

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007333110

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007871694

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007333110

Country of ref document: AU

Date of ref document: 20071210

Kind code of ref document: A